Febrile neutropenia

Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Retrieved on: 
Mardi, décembre 6, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, DSN, SPPI, Hematopoietic stem cell transplantation, Infection, FN, Health, Patient, Cancer, Pegfilgrastim, Research, Febrile neutropenia, Incidence, Medicine, NCCN, Maintenance, Medication, Policy, Journal of the National Comprehensive Cancer Network, Hematopoietic growth factor, Safety, Education, Spectrum Pharmaceuticals, BLA, Risk, Pharmaceutical industry, Neutropenia

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines (NCCN Guidelines) in oncology for Hematopoietic Growth Factors.

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines (NCCN Guidelines) in oncology for Hematopoietic Growth Factors.
  • The NCCN guidelines are a standard resource for determining the best course of treatment and supportive care for people living with cancer.
  • The inclusion in the NCCN guidelines further reinforces the clinical profile of ROLVEDON and is an important milestone for the program.
  • REDEFINING CANCER CARE and ROLVEDON are the Spectrum Pharmaceuticals logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor

Retrieved on: 
Mardi, décembre 13, 2022
Therapy, Poster, IWG, MD, Society, Leukemia, HPK1, Science, TCR, Cancer, Decitabine, MD Anderson Cancer Center, Acute myeloid leukemia, TP53, Treadwell, Multicenter Automatic Defibrillator Implantation Trial, Division, AE, Azacitidine, TTK, Chronic myelomonocytic leukemia, AML, Myelodysplastic syndrome, PLK4, ELN, Toxic leukoencephalopathy, ASH, AES, PD, Febrile neutropenia, Pharmaceutical industry, Tolerability, Safety, Patient

The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.

Key Points: 
  • The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.
  • "CFI-400945 had previously shown single agent complete remissions in refractory high risk AML.
  • Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 (TTK inhibitor) and CFI-402411 (HPK1 inhibitor).

Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor

Retrieved on: 
Mardi, décembre 13, 2022
Therapy, Poster, IWG, MD, Society, Leukemia, HPK1, Science, TCR, Cancer, Decitabine, MD Anderson Cancer Center, Acute myeloid leukemia, TP53, Treadwell, Multicenter Automatic Defibrillator Implantation Trial, Division, AE, Azacitidine, TTK, Chronic myelomonocytic leukemia, AML, Myelodysplastic syndrome, PLK4, ELN, Toxic leukoencephalopathy, ASH, AES, PD, Febrile neutropenia, Pharmaceutical industry, Tolerability, Safety, Patient

The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.

Key Points: 
  • The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.
  • "CFI-400945 had previously shown single agent complete remissions in refractory high risk AML.
  • Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 (TTK inhibitor) and CFI-402411 (HPK1 inhibitor).

Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH Annual Meeting

Retrieved on: 
Lundi, décembre 12, 2022
Pneumonia, Intracranial hemorrhage, Society, Research, Toxicity, Anemia, Aplastic anemia, Child, Acute kidney injury, Ōtsuka, NCCN, Woman, Patient, Sepsis, MDS, Bone marrow suppression, Risk, CMML, Thrombocytopenia, Fatal, Microdeletion syndrome, MLF, International Prognostic Index, AUC, MOS, Birth, Febrile neutropenia, Clinical trial, National Comprehensive Cancer Network, Abstract, Neutropenia, Creatinine, ESRD, Pregnancy, De novo, Decitabine, Chronic kidney disease, TP53, Confidence interval, ASH, Mutation, Chronic myelomonocytic leukemia, Route of administration, Internal medicine, Sudden death, LFS, Kidney, Septic shock, Myelodysplastic syndrome, Vanderbilt University, Astex, Chromosomal deletion syndrome, IV, Fetus, Pharmaceutical industry, Birth control, Epidemiology, MD

PRINCETON, N.J. and PLEASANTON, Calif., Dec. 12, 2022 /PRNewswire/ -- Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced preliminary data from the Phase 3 ASCERTAIN trial assessing overall and leukemia-free survival in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML) harboring biallelic TP53 mutations following treatment with oral decitabine and cedazuridine (ASTX727). The data are being presented today as an oral presentation (Abstract #854) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The data are being presented today as an oral presentation ( Abstract #854 ) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.
  • In the study, the population of patients harboring a TP53 mutation (44 of 125 patients) was characterized by allelic status: 14 patients had biallelic mutations and 30 patients had monoallelic mutations without other chromosomal deletions.
  • The primary endpoint of the study was total 5-day area-under-the-curve (AUC) equivalence of oral decitabine and cedazuridine and IV decitabine.
  • Astex, the Astex logo, Taiho Oncology, the Taiho Oncology logo and INQOVI are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries.

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

Retrieved on: 
Mardi, décembre 6, 2022
Therapy, BCMA, Security (finance), Oncology, European Society for Medical Oncology, Lung, Therapeutic index, B-cell maturation antigen, MUC1, Diagnosis, Epithelium, Patient, University of Maryland Medical Center, Cancer, Degenerative disease, Toxicity, Assistant professor, Roche, Breast cancer, GVHD, Safety, RRMM, University of California, ESMO, Efficacy, Multimedia, Infrared spectroscopy correlation table, University, Breast, Cytokine release syndrome, SAN, CRS, Febrile neutropenia, Vaccine, Pharmaceutical industry, Medical imaging, Risk management, Takeda

SAN DIEGO, Dec. 6, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it will present early clinical results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

Key Points: 
  • "While it is still quite early in both trials, we have seen encouraging responses in both P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the lowest doses as well as favorable tolerability.
  • Poseida has demonstrated the elimination of tumor cells to undetectable levels in preclinical models of both breast and ovarian cancer.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Wearable Injectors Market To Grow USD 4982.4 Million By 2028 With A CAGR of 7.4% | Valuates Reports

Retrieved on: 
Mardi, novembre 29, 2022
COVID-19, Incidence, Infection, Prevalence, Wearable, Naloxone, Patient, Apnea, Cardiac arrest, Arm, USD, Degenerative disease, Death, Medical device, Febrile neutropenia, Cardiovascular disease, Pharmaceutical industry, Health insurance, Cancer

Due to the COVID-19 pandemic, the global Wearable Injectors market size is estimated to be worth USD 3246.5 million in 2022 and is forecast to a readjusted size of USD 4982.4 million by 2028 with a CAGR of 7.4% during the review period.

Key Points: 
  • Due to the COVID-19 pandemic, the global Wearable Injectors market size is estimated to be worth USD 3246.5 million in 2022 and is forecast to a readjusted size of USD 4982.4 million by 2028 with a CAGR of 7.4% during the review period.
  • Additionally, it is projected that the drive to save healthcare costs and the increased demand for continuous monitoring will encourage market growth.
  • Additionally, it is anticipated that growing demand for in-home care will hasten the Wearable Injectors market growth.
  • The Wearable Injectors Market is anticipated to develop as more people with cancer and other chronic conditions need to administer injectable medications.

Wearable Injectors Market To Grow USD 4982.4 Million By 2028 With A CAGR of 7.4% | Valuates Reports

Retrieved on: 
Mardi, novembre 29, 2022
COVID-19, Incidence, Infection, Prevalence, Wearable, Naloxone, Patient, Apnea, Cardiac arrest, Arm, USD, Degenerative disease, Death, Medical device, Febrile neutropenia, Cardiovascular disease, Pharmaceutical industry, Health insurance, Cancer

Due to the COVID-19 pandemic, the global Wearable Injectors market size is estimated to be worth USD 3246.5 million in 2022 and is forecast to a readjusted size of USD 4982.4 million by 2028 with a CAGR of 7.4% during the review period.

Key Points: 
  • Due to the COVID-19 pandemic, the global Wearable Injectors market size is estimated to be worth USD 3246.5 million in 2022 and is forecast to a readjusted size of USD 4982.4 million by 2028 with a CAGR of 7.4% during the review period.
  • Additionally, it is projected that the drive to save healthcare costs and the increased demand for continuous monitoring will encourage market growth.
  • Additionally, it is anticipated that growing demand for in-home care will hasten the Wearable Injectors market growth.
  • The Wearable Injectors Market is anticipated to develop as more people with cancer and other chronic conditions need to administer injectable medications.

Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Retrieved on: 
Vendredi, novembre 25, 2022
Oncology, FDA, Health, General Health, Pharmaceutical, Biotechnology, FDA, Medication, HER2, ODAC, 8-K, CRL, Broadcast license, Spectrum Pharmaceuticals, Lung cancer, NDA, SPPI, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, Quality control, Febrile neutropenia, Endpoint security, Food, Patient, Incidence, Pharmaceutical industry, Fine chemical, Spectrum

Based on the CRL, the Company would have to generate additional data including a randomized controlled study prior to approval.

Key Points: 
  • Based on the CRL, the Company would have to generate additional data including a randomized controlled study prior to approval.
  • The Company will focus efforts on driving growth for its recently launched commercial drug, ROLVEDON.
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliates.
  • REDEFINING CANCER CARE and ROLVEDON are the Spectrum Pharmaceuticals logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Lundi, novembre 21, 2022
The Monarch School, Adult, Cell death, Food and Drug Administration, PI3K, Growth, Cancer, EMBER, Cyclin D1, Recurrence, Plasma, Breast, Febrile neutropenia, PIK3CA, Rb, Woman, Cell proliferation, Diarrhea, SERD, Infection, ER, Tamoxifen, Traffic barrier, CDK, Physician, Cerebrospinal fluid, Eli Lilly and Company, FDA, Breast cancer, Breast cancer classification, Phosphorylation, ESR1, ET, EBC, NYSE, OS, S phase, Hospital, Pharmacology, Patient, Molecular biology, Grade 3, Apoptosis, Toxicity, Risk, Dehydration, Cyclin-dependent kinase, Loperamide, Lilly, Retinoblastoma protein, Food, Cell cycle, Preclinical development, Grade 2, Pharmaceutical industry, Birth control, Medical imaging, Abemaciclib, Neutropenia, G1

INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.

Key Points: 
  • INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.
  • In patients with advanced cancer, including breast cancer, concentrations of Verzenio and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations.

Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection

Retrieved on: 
Vendredi, octobre 21, 2022
Science, Biotechnology, Research, Pharmaceutical, Public Relations, Investor Relations, Health, FDA, Communications, Spectrum Pharmaceuticals, SPPI, Infection, Patient, Pegfilgrastim, Food, Food and Drug Administration, DSN, Febrile neutropenia, Incidence, BLA, Adult, Safety, Hematopoietic stem cell transplantation, Medication, Neutropenia, Nasdaq, Pharmaceutical industry

This is an important milestone in Spectrums transition to a commercial stage company, and we are excited to deliver ROLVEDON to the patients who need it.

Key Points: 
  • This is an important milestone in Spectrums transition to a commercial stage company, and we are excited to deliver ROLVEDON to the patients who need it.
  • ROLVEDON also demonstrated non-inferiority to pegfilgrastim in the mean DSN across all four cycles (all NI p
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliates.
  • REDEFINING CANCER CARE and ROLVEDON are the Spectrum Pharmaceuticals logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.